FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Pharmadrug Inc. (the "Issuer").

Trading Symbol: BUZZ

Number of Outstanding Listed Securities: 83,302,274

Date: March 31, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   The Issuer has been closely monitoring the developments of the current coronavirus ("COVID-19") pandemic and focusing its resources on navigating and adapting to the situation as it unfolds.

   In the current period, management has also continued to work on the audit of the Fiscal 2019 consolidated financial statements.

2. Provide a general overview and discussion of the activities of management.

   As Pharmadrug continues to develop business in Germany, management believes that the Company will see significant growth in 2020. A new sales team was recently put in place in November 2019 that began to execute on a new strategic plan. The Company expects to continue to grow its Bedrocan business and the number of pharmacies in its distribution network significantly over the next six months. Pharmadrug signed two major supply agreements in the fall of 2019, which will supply Pharmadrug Production with medical cannabis under its own brand '**Cannabion.**'

   Management is actively working towards securing two other major types of supply. Firstly, it is in discussions with a current importer to negotiate an opportunity to resell their product in the same manner it is currently selling the Bedrocan product. It is also in major discussions with two Danish companies that are looking to ramp cultivation in the near term. This product can be imported into Germany under Pharmadrug's brand. Management believes Danish product should begin arriving into Germany by Q3 2020. Pharmadrug is aiming to be one of the first importers of Danish product.

   Given the current retail environment, Pharmadrug has decided to hold off on its CannabiSendak investment. Management will decide in the short term whether this decision is indefinite.

In February 2020, Pharmadrug entered into a non-binding letter of intent in regard to the Proposed Transaction, but have not yet entered into any binding agreement. At this time there is no certainty that the Proposed Transaction will be completed in the near future or at all. As discussions with respect to the Proposed Transaction proceed the Company will provide further updates.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   Pharmadrug plans to grow its distribution platform beyond Germany into other European Union ("EU") countries. Pharmadrug Production GmbH, its German subsidiary, is a Schedule I Narcotics distributor which allows the German business to export GMP medical cannabis to other EU countries as and when those countries legalize cannabis. The latest supply agreements with Canada House Wellness Group Inc. and My Green Fields will allow Pharmadrug to provide its German distribution base with additional supply under its own Cannabion brand in a market that remains short in supply. It will also provide access to oils and extracts to serve German pharmacies as well as to other markets in the Eurozone. The Company has recently expanded its sales efforts in effort to enable broader distribution.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   None noted.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   None noted.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   None noted.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None noted.

8. Describe the acquisition of new customers or loss of customers.

None noted.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None noted.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None noted.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None noted.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None noted.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None noted.

14. Provide details of any securities issued and options or warrants granted.

There were no new securities issued by the Company during the month, including grants of options and warrants.

15. Provide details of any loans to or by Related Persons.

None noted.

16. Provide details of any changes in directors, officers or committee members.

None noted.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

For more information related to certain risks and uncertainties that are inherent to the Company's industry, please refer to the "Risk Factors" section of the Management's Discussion and Analysis filed quarterly on SEDAR.

In addition, on January 30, 2020, the World Health Organization declared that the recent COVID-19 outbreak was a global health emergency, recognizing that the disease represents a risk outside of China, where it emerged in the last couple of months. Companies across various industries could be impacted materially by the coronavirus.

COVID-19's known and unknown impact on earnings, costs, employees, supply chains, customers and other stakeholders, as well as other business matters, may be material for the Issuer, and may have a material impact on the Issuer's gross earnings, net earnings and other business matters. Environmental, social and governance factors may also impact the Issuer's operations in the near future.

Certificate of Compliance
The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 6, 2020.

Daniel Cohen
Name of Director or Senior Officer

"Daniel Cohen"
Signature
Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer Pharmadrug Inc. (formerly Aura Health Inc.)	For Month End March 31, 2020	Date of Report YY/MM/DD 20/04/06
Issuer Address 77 King Street West, Suite 2905		
City/Province/Postal Code Toronto/ Ontario/ M5K 1H1	Issuer Fax No. ( )	Issuer Telephone No. (647) 202-1824
Contact Name Keith Li	Contact Position CFO	Contact Telephone No. (647) 660-8703
Contact Email Address kli@bransonservices.com	Web Site Address www.pharmadrug.co	